Previous Close | 58.83 |
Open | 58.83 |
Bid | 55.80 |
Ask | 57.05 |
Strike | 50.00 |
Expire Date | 2025-01-17 |
Day's Range | 58.83 - 58.83 |
Contract Range | N/A |
Volume | |
Open Interest | 16 |
Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.
There will always be a healthcare industry, and it will always be a place to find great long-term stocks. You probably know healthcare conglomerate Johnson & Johnson for some of its former brands, like Tylenol and Band-Aids.
Abbott Laboratories (NYSE: ABT) is seen as a solid safe-harbor stock because of the company's 135-year history, its diversified healthcare business, and its reliable dividend. Abbott is a global company with a huge reach in products and geography. Its segments are diagnostic products, medical devices, nutritional products, and established pharmaceutical products (branded generic medicines).